|
Getting your Trinity Audio player ready...
|
Author: Małgorzata Gryka-Marton, MD
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease that affects various organs and systems, leading to their impairment. The condition predominantly affects women (90% of cases), with initial symptoms usually appearing between the ages of 15 and 45. It is estimated that in Europe, between 30 and 50 people per 100,000 suffer from SLE, whereas in the United States, the prevalence reaches up to 161 per 100,000 individuals.
One of the reasons for the higher prevalence of SLE in the United States may be the larger proportion of the African American population, which exhibits a genetic predisposition to the disease. Research indicates that African Americans are more frequently affected by SLE, and their disease course tends to be more severe compared to Caucasians.
Systemic Lupus Erythematosus – Symptoms and Diagnostic Challenges
Diagnosing SLE is complex, as the disease manifests in various organs, ranging from skin lesions and joint pain to kidney, heart, or nervous system involvement. Symptoms may mimic other rheumatic conditions, leading to delays in diagnosis. Patients often receive ineffective treatments for years, unaware that their therapy could be effectively modified to achieve remission.
One of the critical issues is the lengthy waiting time for a rheumatology consultation. In Poland, it is estimated that the waiting period ranges from 6 to 24 months, significantly delaying diagnosis and the implementation of effective therapy. During this time, disease symptoms may worsen, resulting in irreversible organ damage.
New Therapeutic Approaches and Clinical Trials
Medicover Integrated Clinical Services (MICS) is a leading centre in patient recruitment for clinical trials related to connective tissue diseases. We conduct Phase I, II, and III clinical trials on novel SLE therapies, which include treatments in various forms: tablets, subcutaneous injections, and intravenous infusions. These are international, randomised, double-blind placebo-controlled trials aimed at evaluating the efficacy and safety of innovative drugs.
Our mission is to provide patients with access to the latest therapies in a comfortable environment. Each patient is treated individually – we focus not only on treatment efficacy but also on ensuring a pleasant experience during visits to our facility. Thanks to a predetermined schedule of visits, patients feel well cared for and secure. Through collaboration with physicians running their own practices, we reach a broad patient base, offering them the opportunity to participate in clinical trials.
Challenges in Treatment and the Role of Clinical Trials
Currently available treatment methods are not always effective and, in many cases, fail to achieve complete remission. Attempts to enhance therapeutic efficacy by administering maximum drug doses often lead to adverse effects that are intolerable for patients, resulting in treatment discontinuation. There is an urgent need to develop a safe and effective therapy that patients can use at home. Clinical trials often represent the last hope for patients in achieving remission.
Patients participating in clinical trials experience a sense of care and belonging to a centre where they can seek support at any time. Moreover, the structured nature of clinical trials, with a well-defined care schedule, helps reduce stress associated with the disease, positively impacting the overall treatment process. It is important to emphasise that participation in clinical trials provides access to cutting-edge treatments even before they are officially introduced to the market.
Conclusion
As part of international research initiatives, our facility not only grants patients access to innovative therapies but also actively contributes to the advancement of knowledge regarding Systemic Lupus Erythematosus. Our commitment and individualised approach ensure that patients return to us with confidence, and we take pride in being one of the world’s leading centres in patient recruitment for clinical trials.
For further information on Systemic Lupus Erythematosus clinical trials, please do not hesitate to contact us.
1. What is systemic lupus erythematosus (SLE)?
Systemic lupus erythematosus is a chronic autoimmune disease where the immune system attacks healthy tissues, causing inflammation and damage to various organs and systems.
2. Who is most commonly affected by SLE?
SLE predominantly affects women, particularly between the ages of 15 and 45. People of African American descent are also more frequently and severely affected.
3. Why is diagnosing SLE challenging?
The symptoms of SLE can mimic other rheumatic conditions, and the disease can affect many different organs. As a result, diagnosis is often delayed, especially when access to specialists like rheumatologists is limited.
4. What role do clinical trials play in Systemic Lupus Erythematosus treatment?
Clinical trials provide patients access to innovative therapies that may not yet be available on the market. They offer a structured, supportive care environment and may represent a treatment option when standard therapies are ineffective.
5. How does Medicover Integrated Clinical Services support Systemic Lupus Erythematosus patients?
MICS conducts clinical trials for new SLE treatments and works closely with physicians to offer patients individualised care in a welcoming setting, with timely access to advanced therapies.
References
- Physical Activity and Systemic Lupus Erythematosus Among European Populations: A Two-Sample Mendelian Randomization Study, Frontiers, https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.784922/full, Accessed: 04.04.2025
- Lupus: Causes, Symptoms & Treatment Options, Medicover Hospitals, Accessed 04.04.2025
